Table II.
Characteristics of EF2-derived peptides and results of the MHC stabilization assay.
| Peptide | Position (aa) | Sequence | Score | %MFI increase |
|---|---|---|---|---|
| HLA-A*24:02-binding peptides | ||||
| EF78 | 78–86 | FYELSENDL | 360 | 40.5 |
| EF786 | 786–794 | AYLPVNESF | 252 | 1552.1 |
| EF701 | 701–709 | RFDVHDVTL | 40 | 297.3 |
| EF412 | 412–420 | AFGRVFSGL | 33.6 | 47.9 |
| CMVpp65 328–336 | QYDPVAALF | 1344.1 | ||
| HLA-A*02:01-binding peptides | ||||
| EF292 | 292–300 | LILDPIFKV | 3290 | 183.3 |
| EF739 | 739–747 | RLMEPIYLV | 2426 | 141.1 |
| EF519 | 519–527 | KLVEGLKRL | 705 | 58.9 |
| EF671 | 671–679 | YLNEIKDSV | 642 | 89.6 |
The primary amino acid sequences of human eEF2 were analyzed for consensus motifs for 9-mer peptides capable of binding to HLA-A*24:02 or 02:01 molecules using ProPred-I software. Percentage MFI increase in MHC stabilization assay was calculated as follows: percentage MFI increase = (MFI with the given peptide - MFI without peptide)/(MFI without peptide) × 100.